Hydroxychloroquine hitting the headlines-retinal considerations
Eye (Lond)
.
2020 Jul;34(7):1158-1160.
doi: 10.1038/s41433-020-0934-9.
Epub 2020 May 19.
Authors
Susan M Downes
1
2
,
Bart P Leroy
3
4
,
Srilakshmi M Sharma
5
,
Sobha Sivaprasad
6
7
,
Hélène Dollfus
8
9
Affiliations
1
Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
[email protected]
.
2
Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
[email protected]
.
3
Department of Ophthalmology & Centre for Medical Genetics, Ghent University Hospital & Ghent University, Ghent, Belgium.
4
Division of Ophthalmology & Center for Cellular & Molecular Therapeutics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
5
Oxford Eye Hospital, John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford, UK.
6
Moorfields Eye Hospital, London, UK.
7
Institute of Ophthalmology, London, UK.
8
University Hospitals of Strasbourg, Strasbourg, France.
9
University of Strasbourg, Strasbourg, France.
PMID:
32427967
PMCID:
PMC7236652
DOI:
10.1038/s41433-020-0934-9
No abstract available
Publication types
Editorial
MeSH terms
Antirheumatic Agents* / adverse effects
COVID-19 Drug Treatment*
Humans
Hydroxychloroquine*
Retina* / drug effects
Retinal Diseases* / drug therapy
SARS-CoV-2
Substances
Antirheumatic Agents
Hydroxychloroquine